BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38405900)

  • 21. Early host CD8 T-cell recovery and sensitized anti-donor interleukin-2-producing and cytotoxic T-cell responses associated with marrow graft rejection following nonmyeloablative allogeneic bone marrow transplantation.
    Kraus AB; Shaffer J; Toh HC; Preffer F; Dombkowski D; Saidman S; Colby C; George R; McAfee S; Sackstein R; Dey B; Spitzer TR; Sykes M
    Exp Hematol; 2003 Jul; 31(7):609-21. PubMed ID: 12842706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Graft-versus-leukemia effect in minor antigen mismatched chimeras given delayed donor leucocyte infusion: immunoregulatory aspects and role of donor T and ASGM1-positive cells.
    Sefrioui H; Billiau AD; Waer M
    Transplantation; 2000 Jul; 70(2):348-53. PubMed ID: 10933162
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
    Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
    Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion.
    Claret EJ; Alyea EP; Orsini E; Pickett CC; Collins H; Wang Y; Neuberg D; Soiffer RJ; Ritz J
    J Clin Invest; 1997 Aug; 100(4):855-66. PubMed ID: 9259585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Donor Hematopoietic Stem Cell/Lymphocyte Maintenance Treatment After CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse Following Stem Cell Transplant.
    Li Q; Lyu C; Liu M; Wang J; Mou N; Jiang E; Zhang R; Deng Q
    Cell Transplant; 2023; 32():9636897231158155. PubMed ID: 36879459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased frequency of TIGIT
    Brauneck F; Haag F; Woost R; Wildner N; Tolosa E; Rissiek A; Vohwinkel G; Wellbrock J; Bokemeyer C; Schulze Zur Wiesch J; Ackermann C; Fiedler W
    Oncoimmunology; 2021 Jun; 10(1):1930391. PubMed ID: 34211801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Leucyl-leucine methyl ester-treated haploidentical donor lymphocyte infusions can mediate graft-versus-leukemia activity with minimal graft-versus-host disease risk.
    Hsieh MH; Varadi G; Flomenberg N; Korngold R
    Biol Blood Marrow Transplant; 2002; 8(6):303-15. PubMed ID: 12108916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selection of Tumor-Specific Cytotoxic T Lymphocytes in Acute Myeloid Leukemia Patients Through the Identification of T-Cells Capable to Establish Stable Interactions With the Leukemic Cells: "Doublet Technology".
    García-Guerrero E; Sánchez-Abarca LI; Domingo E; Ramos TL; Bejarano-García JA; Gonzalez-Campos JA; Caballero-Velázquez T; Pérez-Simón JA
    Front Immunol; 2018; 9():1971. PubMed ID: 30233577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunological and Clinical Impact of Manipulated and Unmanipulated DLI after Allogeneic Stem Cell Transplantation of AML Patients.
    Greiner J; Götz M; Bunjes D; Hofmann S; Wais V
    J Clin Med; 2019 Dec; 9(1):. PubMed ID: 31878060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Landscape of T Cells in NK-AML(M4/M5) Revealed by Single-Cell Sequencing.
    Wu W; Liang X; Li H; Huang X; Wan C; Xie Q; Liu Z
    J Leukoc Biol; 2022 Oct; 112(4):745-758. PubMed ID: 35258858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular persistence of chronic myeloid leukemia caused by donor T cells specific for lineage-restricted maturation antigens not recognizing immature progenitor-cells.
    von dem Borne PA; van Luxemburg-Heijs SA; Heemskerk MH; Jedema I; Mulder A; Willemze R; Falkenburg JH
    Leukemia; 2006 Jun; 20(6):1040-6. PubMed ID: 16525495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia.
    Wu CJ; Yang XF; McLaughlin S; Neuberg D; Canning C; Stein B; Alyea EP; Soiffer RJ; Dranoff G; Ritz J
    J Clin Invest; 2000 Sep; 106(5):705-14. PubMed ID: 10974024
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of leukemia relapsed after allogenic bone marrow transplantation with donor lymphocyte infusion: report of 11 cases].
    Sanz Rodríguez C; Steegmann JL; Granda A; de la Cámara R; Figuera A; Arranz R; Gómez-García de Soria V; Alegre A; Fernández-Rañada JM
    Sangre (Barc); 1999 Dec; 44(6):456-63. PubMed ID: 10822760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Graft-versus-leukemia effects from donor lymphocyte infusion after nonmyeloablative allogeneic bone marrow transplantation in mice.
    Du B; Li DP; Xu KL; Pan XY
    Chin Med J (Engl); 2005 Mar; 118(6):474-9. PubMed ID: 15788128
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytotoxic T-lymphocytes in acute myeloid leukemia: Monitoring prognosis and guiding treatment choice.
    Lu M; Yu X; Hu J; Wang J; Wang T
    J Gene Med; 2024 Jan; 26(1):e3587. PubMed ID: 37697474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Herpes simplex thymidine kinase gene-transduced donor lymphocyte infusions.
    Burt RK; Drobyski WR; Seregina T; Traynor A; Oyama Y; Keever-Taylor C; Stefka J; Kuzel TM; Brush M; Rodriquez J; Burns W; Tennant L; Link C
    Exp Hematol; 2003 Oct; 31(10):903-10. PubMed ID: 14550806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PR1-specific cytotoxic T lymphocytes are relatively frequent in umbilical cord blood and can be effectively expanded to target myeloid leukemia.
    St John LS; Wan L; He H; Garber HR; Clise-Dwyer K; Alatrash G; Rezvani K; Shpall EJ; Bollard CM; Ma Q; Molldrem JJ
    Cytotherapy; 2016 Aug; 18(8):995-1001. PubMed ID: 27378343
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens.
    Mutis T; Verdijk R; Schrama E; Esendam B; Brand A; Goulmy E
    Blood; 1999 Apr; 93(7):2336-41. PubMed ID: 10090944
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia.
    Mani R; Rajgolikar G; Nunes J; Zapolnik K; Wasmuth R; Mo X; Byrd JC; Lee DA; Muthusamy N; Vasu S
    Cytotherapy; 2020 Jul; 22(7):369-376. PubMed ID: 32303428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: indications and dose escalation.
    Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y
    Ther Apher; 2001 Feb; 5(1):40-5. PubMed ID: 11258609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.